How does 8VP1's PS Ratio compare to its peers?

8VP1 is expensive based on its Price-To-Sales Ratio (2.8x) compared to the peer average (1x).

How does 8VP1's PS Ratio compare vs other companies in the European Healthcare Services Industry?

8VP1 is expensive based on its Price-To-Sales Ratio (2.8x) compared to the European Healthcare Services industry average (2.4x).

What is 8VP1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 8VP1's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of 8VP1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 8VP1's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Avricore Health (DB:8VP1) - Stock Price, News & Analysis

8VP1 Stock Overview

Engages in the health data and point-of-care technologies business in Canada.

About the company

8VP1 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings have grown 30.2% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (€14M)

Does not have meaningful revenue (CA$4M)

Volatile share price over the past 3 months compared to the German market

Avricore Health Inc. Competitors

MeVis Medical Solutions

XTRA:M3V

€44.4m

DocCheck

XTRA:AJ91

€46.9m

Arzneiwerk VIDA

XTRA:TLIK

€5.0m

CompuGroup Medical SE KGaA

XTRA:COP

€724.8m

Price History & Performance

Summary of all time highs, changes and price drops for Avricore Health
Historical stock prices
Current Share Price	CA$0.088
52 Week High	CA$0.20
52 Week Low	CA$0.073
Beta	-1.88
11 Month Change	-27.46%
3 Month Change	-47.94%
1 Year Change	-11.50%
33 Year Change	2.31%
5 Year Change	4,325.00%
Change since IPO	-93.13%

Recent updates

Shareholder Returns

	8VP1	DE Healthcare Services	DE Market
7D	-5.3%	21.0%	-1.4%
1Y	-11.5%	-28.1%	11.8%

Return vs Industry: 8VP1 exceeded the German Healthcare Services industry which returned -29.8% over the past year.

Return vs Market: 8VP1 underperformed the German Market which returned 13.9% over the past year.

Price Volatility

Is 8VP1's price volatile compared to industry and market?
8VP1 volatility
8VP1 Average Weekly Movement	10.4%
Healthcare Services Industry Average Movement	5.3%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 8VP1's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 8VP1's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1996	n/a	Hector Bremner	avricore.com

Avricore Health Inc. engages in the health data and point-of-care technologies business in Canada. It provides HealthTab, a turnkey point-of-care testing platform that turns pharmacies into community point-of-care diagnostic centers. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018.

Avricore Health Inc. Fundamentals Summary

How do Avricore Health's earnings and revenue compare to its market cap?
8VP1 fundamental statistics
Market cap	€9.45m
Earnings (TTM)	-€1.95k
Revenue (TTM)	€2.99m

2.8x

P/S Ratio

-4,323x

P/E Ratio

Is 8VP1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8VP1 income statement (TTM)
Revenue	CA$4.48m
Cost of Revenue	CA$2.86m
Gross Profit	CA$1.62m
Other Expenses	CA$1.62m
Earnings	-CA$2.92k

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.000029
Gross Margin	36.16%
Net Profit Margin	-0.065%
Debt/Equity Ratio	0%

How did 8VP1 perform over the long term?

See historical performance and comparison

8VP1 Stock Overview

Rewards

Risk Analysis

Avricore Health Inc. Competitors

XTRA:M3V

€44.4m

XTRA:AJ91

€46.9m

XTRA:TLIK

€5.0m

XTRA:COP

€724.8m

Price History & Performance

Recent News & Updates

Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.002 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in FY 2022)

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

New major risk - Market cap size

Insufficient new directors

Recent updates

Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.002 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in FY 2022)

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

New major risk - Market cap size

Insufficient new directors

Third quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 3Q 2022)

Avricore Health Inc. Expands Its Innovative Point-Of-Care Chronic and Infectious Disease Screening and Health- Data Management Platform, Healthtab

Second quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 2Q 2022)

Avricore Health Inc. Announces Board Changes

First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 1Q 2022)

Avricore Health Inc., Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: CA$0.008 loss per share (vs CA$0.018 loss in FY 2021)

Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2021)

High number of new directors

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.009 loss in 1Q 2021)

Avricore Health Inc., Annual General Meeting, Jul 21, 2022

High number of new and inexperienced directors

Full year 2021 earnings released: CA$0.018 loss per share (vs CA$0.019 loss in FY 2020)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Avricore Health Inc Begins Patient Testing on the HealthTab™ Platform in Select Shoppers Drug Mart® Pharmacies

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

Avricore Health Inc. Patient Testing Has Begun on the First Deployment of the New HealthTab

Avricore Health Inc. Begins Patient Testing on First Deployment of New HealthTabTM-Integrated Afinion 2TM Analyzers in Initial Shoppers Drug Mart® Pharmacy Location

Avricore Health Inc. Signs Master Agreement to Pilot Healthtab Platform for Diabetes Management in Select Shoppers Drug Mart Pharmacies

Avricore Health Inc. Successfully Launches HealthTab™ in the First of 11 Shoppers Drug Mart Pilot Locations

Avricore Health's HealthTab Achieves Critical Milestones in Connecting New Testing Device

First quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.004 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.019 loss per share (vs CA$0.041 loss in FY 2019)

Avricore Health Inc. Signs Letter of Intent with Avrok Laboratories

Avricore Health Inc. announced that it has received CAD 1.54 million in funding

Whole Health Pharmacy Partners to Launch Avricore’s Healthtab™

New 90-day high: €0.36

Avricore Health Inc. announced that it expects to receive CAD 1.54 million in funding

Avricore Health Inc. Announces Board Changes

Avricore Health Inc. announced that it has received CAD 1.5 million in funding

Avricore Health Inc. Successfully Intergrates ID Now™ Rapid PCR Test Device, Offering Real-Time Covid-19 Reporting Direct from Instrument for First Time

Avricore Health Announces Management Changes

Third quarter 2020 earnings released: CA$0.003 loss per share

Avricore Health Inc. announced that it expects to receive CAD 1.5 million in funding

Healthtab Integrating New Device to Add Hba1c Blood Glucose Testing to Its Real-Time Data Reporting System